טוען...
Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study
BACKGROUND: Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS). More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo patients and patients in early therapy escalation. OBJECTIVE: To investigate the safety and efficacy of off-label t...
שמור ב:
| הוצא לאור ב: | Mult Scler J Exp Transl Clin |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7970692/ https://ncbi.nlm.nih.gov/pubmed/33796328 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217320973049 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|